<DOC>
	<DOC>NCT01430429</DOC>
	<brief_summary>The purpose of the study is to assess safety and efficacy of multiple doses of NI-0801 in primary biliary cirrhosis patients with an inadequate response to ursodeoxycholic acid.</brief_summary>
	<brief_title>Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis, Biliary</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Proven primary biliary cirrhosis (PBC), as demonstrated by the presence of at least 2 of the following 3 diagnostic factor (History of increased alkaline phosphatase levels for at least 6 months; positive serum AMA titer; Liver biopsy consistent with PBC) Elevated liver enzyme levels at screening Have given written informed consent Screening bilirubin &gt; 2.9 mg/dL (50 Î¼mol/L) Screening creatinine clearance &lt; 80 ml/min History or presence of hepatic decompensation (e.g., esophageal variceal bleeding, hepatic encephalopathy, or ascites) Positive serology result for Human Immunodeficiency Virus (HIV), Hepatitis B or C Known or previous diagnosis of malignancy Presence of any active infection Previous history of active TB within 12 months of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>